{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:53:59Z","timestamp":1793904839174,"version":"4.8.0"},"reference-count":33,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant Pseudomonas aeruginosa (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (p = 0.033) and Cmin (p = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (p = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF.<\/jats:p>","DOI":"10.3390\/antibiotics12061078","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T01:35:11Z","timestamp":1687311311000},"page":"1078","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model"],"prefix":"10.3390","volume":"12","author":[{"given":"Vaughn D.","family":"Craddock","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Kansas School of Pharmacy, Lawrence, KS 66047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan L.","family":"Steere","sequence":"additional","affiliation":[{"name":"Department of Population Health, University of Kansas School of Medicine, Kansas City, KS 66160, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Harman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Kansas School of Pharmacy, Lawrence, KS 66047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Britt","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Kansas School of Pharmacy, Lawrence, KS 66047, USA"},{"name":"Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS 66160, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bhagirath, A.Y., Li, Y., Somayajula, D., Dadashi, M., Badr, S., and Duan, K. (2016). Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm. Med., 16.","DOI":"10.1186\/s12890-016-0339-5"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"ref_4","unstructured":"Cystic Fibrosis Foundation (2017). Annual Data Report, Cystic Fibrosis Foundation."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1945892418815615","article-title":"Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity against Pseuodomonas aeeurginosa","volume":"33","author":"Cho","year":"2019","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/crj.13262","article-title":"Delafloxacin\u2014A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"15","author":"Millar","year":"2021","journal-title":"Clin. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11130","article-title":"Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung","volume":"487","author":"Pezzulo","year":"2012","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","article-title":"Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens","volume":"48","author":"Thabit","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.03482-14","article-title":"Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates","volume":"58","author":"Siala","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1172\/JCI24684","article-title":"Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions","volume":"116","author":"Yoon","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ejcb.2018.06.001","article-title":"Extracellular pH and lung infections in cystic fibrosis","volume":"97","year":"2018","journal-title":"Eur. J. Cell Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16083","DOI":"10.1073\/pnas.2634339100","article-title":"Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium","volume":"100","author":"Coakley","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1183\/09031936.03.00027603","article-title":"Airway surface pH in subjects with cystic fibrosis","volume":"21","author":"McShane","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1128\/AEM.71.5.2501-2510.2005","article-title":"Application of a pH-sensitive fluoroprobe (C-SNARF-4) for pH microenvironment analysis in Pseudomonas aeruginosa biofilms","volume":"71","author":"Hunter","year":"2005","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_17","unstructured":"(2017). Baxdela (Delafloxacin) [Package Insert], Melinta Therapeutics, Inc."},{"key":"ref_18","unstructured":"(2022). Performance Standards for Antimicrobial Susceptibility Testing\u201432nd Edition (Standard No. CLSI M100-Ed32)."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review","volume":"18","author":"Somayaji","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.01721-15","article-title":"OligoG CF-5\/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model","volume":"60","author":"Hengzhuang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0966-842X(00)01913-2","article-title":"Mechanisms of biofilm resistance to antimicrobial agents","volume":"9","author":"Mah","year":"2001","journal-title":"Trends Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/pathogens2020288","article-title":"From in vitro to in vivo Models of Bacterial Biofilm-Related Infections","volume":"2","author":"Lebeaux","year":"2013","journal-title":"Pathogens"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0065-2164(09)69004-3","article-title":"Chapter 4: In vitro biofilm models: An overview","volume":"Volume 69","author":"McBain","year":"2009","journal-title":"Advances in Applied Microbiology"},{"key":"ref_24","first-page":"e3857","article-title":"Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung","volume":"64","author":"Kirchner","year":"2012","journal-title":"J. Vis. Exp."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Haley, C.L., Colmer-Hamood, J.A., and Hamood, A.N. (2012). Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium. BMC Microbiol., 12.","DOI":"10.1186\/1471-2180-12-181"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.1073\/pnas.131087598","article-title":"Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity","volume":"98","author":"Jayaraman","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/thorax.57.11.926","article-title":"Airways in cystic fibrosis are acidified: Detection by exhaled breath condensate","volume":"57","author":"Tate","year":"2002","journal-title":"Thorax"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1128\/JB.01138-07","article-title":"Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum","volume":"189","author":"Palmer","year":"2007","journal-title":"J. Bacteriol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pereira, L.C., Fatima, M.A., Santos, V.V., Brandao, C.M., Alves, I.A., and Azeredo, F.J. (2022). Pharmacokinetic\/Pharmacodynamic Modeling and Application in Antibacterial and Antifungal Pharmacotherapy: A Narrative Review. Antibiotics, 11.","DOI":"10.3390\/antibiotics11080986"},{"key":"ref_30","unstructured":"(2019). Performance Standards for Antimicrobial Susceptibility Testing\u201429th Edition (Standard No. CLSI M100-Ed29)."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1099\/jmm.0.45969-0","article-title":"Microcolony formation: A novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung","volume":"54","author":"Sriramulu","year":"2005","journal-title":"J. Med. Microbiol."},{"key":"ref_32","unstructured":"(2016). Cipro (Ciprofloxacin) [Package Insert], Bayer HealthCare Pharmaceuticals."},{"key":"ref_33","unstructured":"(2008). Levaquin (Levofloxacin) [Package Insert], Ortho-McNeil-Janssen Pharmaceuticals."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/1078\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:56:59Z","timestamp":1760126219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/1078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["antibiotics12061078"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12061078","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}